Dropped head syndrome: Report of three cases during treatment with a mek inhibitor

Neurology

Volumn 79, Issue 18, 2012, Pages 1929-1931

  Chen, Xi ^a   Schwartz, Gary K ^b   DeAngelis, Lisa M ^a   Kaley, Thomas ^a   Carvajal, Richard D ^b  

^a Parkinson's Disease and Related Disorders Clinic   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; SELUMETINIB;

AGED; BREAST METASTASIS; CASE REPORT; CHOROID MELANOMA; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DROPPED HEAD SYNDROME; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MUSCLE DISEASE; NOTE; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; UVEA MELANOMA;

EID: 84871344371     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318271f87e     Document Type: Article

References (6)

1. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 2007;13:1576-1583.
2. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, openlabel, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555-567.
3. Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011;29: 1114-1121.
4. Boasberg PD, Redfern CH, Daniels GA, Bodkin D, Garrett CR, Ricart AD. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol 2011;68:547-552.
5. Al-Nahhas A, Jawad AS. PET/CT imaging in inflammatory myopathies. Ann NY Acad Sci 2011;1228:39-45.
6. Kramer HF, Goodyear LJ. Exercise, MAPK, and NFkappaB signaling in skeletal muscle. J Appl Physiol 2007; 103:388-395.